Heart Shield Elite

Heart Shield Elite — Advanced 360° Cardiovascular Risk Assessment (SGD 899)

Heart Shield Elite is EMIS+'s most comprehensive cardiovascular risk stratification protocol, integrating seven distinct biomarker domains, genetic polygenic risk scoring, non-invasive vascular imaging, and electrocardiographic assessment into a single coordinated clinical evaluation. The protocol quantifies both short-term (10-year Pooled Cohort Equations / SCORE2) and lifetime atherosclerotic cardiovascular disease (ASCVD) risk, then translates findings into a personalised cardiac protection protocol aligned with ACC/AHA 2023, ESC/EAS 2021, and Singapore MOH Cardiovascular Prevention Clinical Practice Guidelines.

Inflammatory and Cardiac Biomarker Panel: High-sensitivity C-reactive protein (hsCRP, IFCC-standardised, LoD ≤0.1 mg/L) stratifies residual inflammatory risk beyond LDL-C control. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI, Roche Elecsys platform, 99th-percentile URL) screen for subclinical myocardial stress and early heart failure. Homocysteine (HPLC enzymatic, µmol/L), fibrinogen (Clauss method, g/L), and D-dimer (VIDAS immunoassay, µg/mL FEU) complete the thromboinflammatory axis.

Advanced Lipid Panel: Beyond standard LDL-C, the protocol measures lipoprotein(a) [Lp(a), isoform-independent immunoturbidimetric assay, reported in nmol/L per EAS Consensus Statement 2022], oxidised LDL (oxLDL, mU/L, ELISA), apolipoprotein B (ApoB, g/L, immunonephelometry — direct measure of atherogenic particle count), and apolipoprotein A-1 (ApoA-1, g/L) with ApoB/ApoA-1 ratio computed. These analytes identify atherogenic dyslipidaemia undetected by conventional LDL-C measurement.

Genetic Cardiovascular Polygenic Risk Score (CAD-PRS): A validated multi-SNP coronary artery disease polygenic risk score (CAD-PRS, ≥6.6 million SNPs, genome-wide chip genotyping) places the individual's inherited CAD susceptibility in population-referenced percentile tiers (quintiles/deciles). Individuals in the top 5% carry risk equivalent to a monogenic familial hypercholesterolaemia mutation. Results are interpreted in conjunction with measured biomarkers per the American Heart Association 2023 Precision Medicine Advisory.

Arterial Stiffness — Pulse Wave Velocity (PWV): Carotid-femoral pulse wave velocity (cf-PWV, m/s, applanation tonometry) measures aortic stiffness — an independent predictor of cardiovascular events validated in the CAFE, ADVANCE, and Framingham Offspring cohorts. Results are age/sex/blood-pressure-referenced per ESH/ESC 2023 hypertension guidelines (pathological threshold: cf-PWV >10 m/s).

Carotid Intima-Media Thickness (CIMT) Ultrasound: B-mode ultrasound of the common carotid artery bilateral segments (ASE/EACVI 2008 protocol, automated edge-detection software) measures intima-media thickness in millimetres and identifies carotid atherosclerotic plaque. CIMT >75th age/sex percentile reclassifies intermediate-risk individuals to high risk per ACC/AHA 2018 guidelines; plaque presence is independently associated with 2× increased MACE risk (CAPS, Rotterdam Study, MESA).

Resting 12-Lead ECG: Physician-reported resting electrocardiogram screens for left ventricular hypertrophy (Sokolow-Lyon/Cornell voltage criteria), ST-T abnormalities, conduction defects (LBBB, RBBB, fascicular blocks), QTc prolongation (Bazett/Fridericia formula, ms), and arrhythmias including silent atrial fibrillation. ECG LVH independently adds predictive value for incident heart failure and stroke beyond conventional risk factors.

Composite Risk Outputs: Heart Health Age (HHA) — the age of a normotensive, non-smoking, lipid-optimal reference individual carrying equivalent cardiovascular risk — is calculated from the full biomarker + imaging dataset. 10-year ASCVD risk is computed via Pooled Cohort Equations (PCE, ACC/AHA 2013, updated 2023) and SCORE2 (European SCORE2 Working Group 2021) with reclassification where indicated. Lifetime ASCVD risk (Framingham Lifetime Risk model) contextualises risk for shared decision-making. All results delivered in a structured physician report with evidence-based intervention recommendations.

Q1: Why is ApoB superior to LDL-C as a therapeutic target, and what does Heart Shield Elite add beyond a standard lipid panel?

Standard LDL-C (Friedewald or Martin-Hopkins calculation) estimates the cholesterol mass within LDL particles but does not directly count atherogenic particles. Each LDL, IDL, VLDL, Lp(a), and chylomicron remnant carries exactly one apolipoprotein B molecule; therefore ApoB concentration is a direct, particle-number measure of atherogenic burden. Multiple Mendelian randomisation studies and the ApoB vs LDL-C Collaborative Analysis (JAMA 2021) demonstrate that ApoB is a stronger predictor of MACE than LDL-C, particularly in patients with metabolic syndrome, hypertriglyceridaemia, or insulin resistance — conditions producing "small dense LDL" with normal calculated LDL-C. Lp(a) — a genetically determined LDL-like particle with prothrombotic properties — is unmeasured in standard panels yet elevates CAD and aortic stenosis risk in approximately 20% of the global population. Heart Shield Elite measures both ApoB and Lp(a) (in nmol/L, the unit endorsed by the EAS 2022 Consensus Statement for clinical decisions), enabling reclassification of patients who appear low-risk on conventional panels but carry significant residual atherogenic burden.

Q2: How does the cardiovascular polygenic risk score (CAD-PRS) interact with measured biomarkers, and how is the result actionable?

The CAD-PRS aggregates the cumulative effect of millions of common genetic variants — each conferring small individual risk — into a composite score benchmarked against a reference population. Unlike monogenic familial hypercholesterolaemia (FH) mutations, a high CAD-PRS does not mandate a single intervention; rather, it identifies individuals whose cardiovascular risk trajectory is steeper than their current biomarker snapshot suggests, and for whom early, intensive prevention is cost-effective. The landmark Khera et al. 2018 Nature Genetics study demonstrated that individuals in the top 8% CAD-PRS quintile carry a threefold lifetime risk equivalent to FH carriers. Crucially, the same study showed that adherence to a healthy lifestyle attenuated CAD incidence by approximately 46% even in the highest genetic risk group — establishing that high CAD-PRS is not deterministic but actionable. Heart Shield Elite integrates CAD-PRS results with hsCRP (inflammatory risk), Lp(a) (fixed atherogenic burden), and CIMT/PWV (subclinical vascular damage) to produce a biologically coherent risk narrative: genetic predisposition × current inflammatory state × existing arterial injury = personalised risk tier and intervention intensity.

Q3: What is the clinical utility of carotid intima-media thickness (CIMT) ultrasound in an asymptomatic individual?

CIMT ultrasound provides a direct, non-invasive measure of subclinical atherosclerosis — the preclinical stage during which arterial wall thickening and plaque accumulation occur decades before symptomatic CAD, stroke, or peripheral arterial disease. In intermediate-risk individuals (10-year PCE 7.5–20%), ACC/AHA 2018 Cholesterol Guidelines designate CIMT as a risk-enhancing factor capable of upward-reclassifying borderline risk patients to statin initiation thresholds (Class IIa recommendation). Population studies — including the Multi-Ethnic Study of Atherosclerosis (MESA), Rotterdam Study, and Carotid Atherosclerosis Progression Study (CAPS) — demonstrate that CIMT >75th age/sex percentile independently doubles the risk of subsequent myocardial infarction and stroke. Carotid plaque presence (echogenic or mixed lesion ≥1.5 mm or ≥50% lumen narrowing) is associated with a 2–3× increase in MACE after controlling for Framingham risk score. The ASE/EACVI protocol used in Heart Shield Elite employs automated edge-detection software (QIMT) to eliminate operator variability and ensure reproducible, guideline-compliant measurements bilaterally.

Q4: Can elevated hsCRP, NT-proBNP, or homocysteine results be acted upon in isolation, or must they be interpreted within the full Heart Shield Elite report?

Isolated biomarker elevation requires contextualisation; standalone interpretation risks both over- and under-treatment. hsCRP is a nonspecific acute-phase reactant elevated by infections, autoimmune conditions, obesity, and physical trauma — its cardiovascular predictive value (as established in the JUPITER trial, Ridker et al.) is valid only when LDL-C is controlled and acute illness is excluded. NT-proBNP similarly rises with atrial fibrillation, renal dysfunction, anaemia, and pulmonary hypertension beyond primary myocardial stress. Homocysteine elevation reflects nutritional deficiency (B12, folate, B6), renal insufficiency, or genetic hyperhomocysteinaemia (MTHFR C677T, CBS mutation) — and while associated with cardiovascular risk in observational data, B-vitamin supplementation has not uniformly reduced MACE in RCTs (VISP, NORVIT), necessitating careful clinical interpretation. Heart Shield Elite's integrated physician report interprets each analyte within the full clinical context — genetic predisposition, arterial stiffness, structural ECG changes, and composite risk scores — ensuring that intervention recommendations are calibrated, evidence-based, and aligned with ACC/AHA 2023 and Singapore MOH Clinical Practice Guidelines.

Q5: What specific interventions does the personalised cardiac protection protocol recommend for different risk tiers?

The personalised cardiac protection protocol generated by Heart Shield Elite stratifies individuals into three actionable risk tiers based on composite biomarker, imaging, genetic, and ECG findings. Tier A (low-intermediate composite risk, Heart Health Age ≤5 years above chronological age, 10-year ASCVD <7.5%): Lifestyle optimisation protocol — dietary intervention targeting Mediterranean-pattern adherence (PREDIMED-Plus evidence base), structured aerobic exercise (≥150 min/week moderate-intensity, ACC/AHA Class I), sleep hygiene optimisation, and 12-month reassessment schedule. Tier B (intermediate-high risk, Heart Health Age 5–15 years above chronological, 10-year ASCVD 7.5–20%, or presence of CIMT plaque/elevated Lp(a)/high CAD-PRS quintile): Statin initiation discussion (rosuvastatin/atorvastatin, ACC/AHA Class IIa–I), structured cardiologist or preventive medicine physician referral, cardiac rehabilitation-grade exercise programme, and reassessment at 6 months. Tier C (high-very high risk, 10-year ASCVD >20%, Heart Health Age >15 years above chronological, abnormal ECG/NT-proBNP/hs-cTnI, or cf-PWV >12 m/s): Urgent specialist cardiology referral, intensive LDL-C reduction targeting ApoB <0.7 g/L (ESC/EAS Class I, very-high-risk), consideration of ezetimibe or PCSK9 inhibitor add-on, antihypertensive optimisation, and reassessment at 3 months.

Regulatory and Methodological Framework: Heart Shield Elite is conducted within an ISO 15189:2022-accredited medical laboratory network with CAP (College of American Pathologists) external quality assurance programmes including EQAS, RIQAS, and Bio-Rad Liquichek. All biochemical assays comply with IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) reference measurement procedures and WHO/IFCC International Reference Preparations where applicable. Genetic CAD polygenic risk scoring methodology follows the Khera et al. 2018 Nature Genetics landmark study (PRSice-2 / LDpred2 algorithms) and the American Heart Association 2023 Precision Medicine in Cardiovascular Disease Advisory. Advanced lipid reporting (Lp(a) in nmol/L) complies with the 2022 European Atherosclerosis Society (EAS) Lipoprotein(a) Consensus Statement. Arterial stiffness measurement follows ESH/ESC 2023 hypertension guidelines pathological thresholds. CIMT protocol adheres to ASE/EACVI 2008 consensus standards. 10-year cardiovascular risk is computed via the 2013/2023 ACC/AHA Pooled Cohort Equations (PCE) and the European SCORE2 algorithm (SCORE2 Working Group, European Heart Journal 2021). Lifetime ASCVD risk uses the Framingham Heart Study Lifetime Risk model. All clinical interpretation and cardiac protection protocol recommendations are aligned with ACC/AHA 2023 Cardiovascular Prevention Guidelines, ESC/EAS 2021 Dyslipidaemia Management Guidelines, and Singapore Ministry of Health Clinical Practice Guidelines on Cardiovascular Prevention. This assessment is conducted under the supervision of MOH-registered physicians in Singapore. Results are not intended to replace clinical consultation; participants with abnormal findings are advised to seek specialist cardiology review. Heart Shield Elite is indicated for adults aged 30–75 years with no prior MACE who are seeking proactive cardiovascular risk quantification and evidence-based prevention.